(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 174.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Crinetics Pharmaceuticals's revenue in 2024 is $4,013,000.On average, 3 Wall Street analysts forecast CRNX's revenue for 2024 to be $266,623,050, with the lowest CRNX revenue forecast at $172,598,581, and the highest CRNX revenue forecast at $347,981,010. On average, 7 Wall Street analysts forecast CRNX's revenue for 2025 to be $2,234,455,661, with the lowest CRNX revenue forecast at $208,788,606, and the highest CRNX revenue forecast at $6,590,064,367.
In 2026, CRNX is forecast to generate $6,052,433,707 in revenue, with the lowest revenue forecast at $1,899,976,315 and the highest revenue forecast at $16,045,404,371.